Rheumatoid Arthritis in 7 Major Markets - Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

The "Rheumatoid Arthritis - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the RA, historical and forecasted epidemiology as well as the RA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The RA market report provides current treatment practices, emerging drugs, RA market share of the individual therapies, current and forecasted RA market size from 2017 to 2030 segmented by seven major markets. The report also covers current RA treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Epidemiology

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-Wise Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.

• The United States, in 2017, accounted for 1,333,290 RA prevalent cases, which are expected to grow during the study period, i.e., 2017-2030.
• In the year 2017, the total prevalent cases of RA in EU5 were 1,956,920, which are expected to grow during the study period, i.e., 2017-2030.
• In the year 2017, the total prevalent cases of RA in Japan were 1,066,584, which are expected to grow during the study period, i.e., 2017-2030.

Drug Chapters

Drug chapter segment of the RA report encloses the detailed analysis of RA marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the RA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Approved Drugs

• Olumiant/Baricitinib (Eli Lilly and Company/Incyte Corporation)
• Rinvoq/Upadacitinib (AbbVie)
• Xeljanz/Tofacitinib (Pfizer/PF Prism CV)
• Remicade/Infliximab (Janssen Biotech/Centocor)
• Enbrel/Etanercept (Immunex/Amgen)
• MabThera/Rituxan/Rituximab (Genentech/Biogen)
• Cimzia/Certolizumab-pegol (UCB)
• Simponi/Golimumab (Jannsen Biotech)
• Humira/Adalimumab (Abbvie)
• Orencia/Abatacept (Bristol Myers Squibb)
• Smyraf/Peficitinib (Astellas Pharma)
• Actemra/Tocilizumab (Roche)
• Kineret/Anakinra (Amgen/Swedish Orphan Biovitrum AB)
• Kevzara/Sarilumab (Regeneron and Sanofi/Asahi Kasei Pharma)

Emerging Drugs

• Otilimab/GSK3196165 (GlaxoSmithKline)
• Filgotinib/GS-6034/GLPG0634/Jyseleca (Gilead and Galapagos NV)
• Olokizumab (R Pharm)
• Ozoralizumab/TS-152 (Taisho Pharmaceuticals/Ablynx)
• ATI-450/CDD-450 (Aclaris Therapeutics)
• VIB4920 (Viela Bio)
• Branebrutinib (Bristol Myers Squibb)
• ABBV-3373 and ABBV-154 (AbbVie)
• Dekavil/F8IL10 (Pfizer/Philogen)
• PF-06651600/Ritlecitinib (Pfizer)
• JTE-051 (Akros Pharma/Japan Tobacco)
• Evobrutinib/M2951 (Merck)
• PF-06650833 (Pfizer)
• Fenebrutinib/GDC-0853/RG7845 (Roche/Genentech)
• MPC-300-IV/ Allogeneic Mesenchymal Precursor Cells (Mesoblast)
• Bimekizumab (UCB Pharma/PRA HEALTH SCIENCES)
• Namilumab/IZN-101/AMG203 (Izana Bioscience/Takeda)
• ABX464 (Abivax)
• HB-AdMSCs (Hope Biosciences)
• SKI-O-703 (Genosco/Oscotec)

RA Market Outlook

RA is an autoimmune disease for which several effective treatment options are present. Currently, there are three primary treatment options for severe and advancing RA which include DMARDs, NSAIDs, and corticosteroids. Early treatment of RA patients with DMARDs significantly decreases these complications. Methotrexate is an excellent, economical first-line DMARD used to treat a majority of RA patients. While most patients respond well to MTX, many continue to have active disease.

DMARDs are immunosuppressive and immunomodulatory agents and are classified as either conventional DMARDs or biologic DMARDs. Biologic DMARDs are rapidly effective in retarding the progression of the joint damage caused by RA. Tumor necrosis factor (TNF) is a messenger protein that promotes inflammation in joints. Biologic medications such as Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), and Cimzia (certolizumab pegol) are all TNF inhibitors that prevent the recruitment of the cells that cause inflammation, bringing rapid symptom relief. It is worth noting that, prior to 2009, Enbrel, Remicade, and Humira were only three TNF inhibitors dominating the market of RA in the United States. Apart from this, T-cell costimulatory blocking agents (Orencia), B-cell depleting agents (Rituxan), interleukin-6 (IL-6) inhibitors (Actemra), and interleukin-1 (IL-1) receptor antagonists (Kineret), have also been approved over the past few years for the management of RA.

Companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.

In conclusion, it can be summarized that as many potential therapies are being investigated for the management of RA, it is safe to predict that the treatment space will experience a significant impact during the forecast period of 2020-2030.

Key Findings

The RA market size in the 7MM is expected to change during the study period 2017-2030. The therapeutic market of RA in the seven major markets was USD 21,184.4 million in 2017 which is expected to increase during study period (2017-2030). According to the estimates, the highest market size of RA is found in the United States followed by Japan and Germany.

The United States Market Outlook

In 2017, the total market size of RA therapies was USD 13,152 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of RA therapies was USD 5,038.2 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of RA therapies in Japan was USD 2,994.6 million in 2017 which is expected to increase in the study period (2017-2030).

Drugs Uptake

Among the recently launched and upcoming therapies, upadacitinib and filgotinib has the potential to impact the market owing to more selective oral JAK1 inhibitor and better clinical profile compared to already approve JAKi. Although upadacitinib will have slight edge over filgotinib owing to order of entry and slightly better efficacy data.

Access and Reimbursement Scenario

European League Against Rheumatism (EULAR) updated recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs).

Leflunomide or sulfasalazine was considered as part of first-line treatment if patients experience early intolerance. Other conventional synthetic DMARDs in the absence of poor prognostic factors was recommended if the treatment target was not achieved after the first-line conventional synthetic DMARD strategy.

A biologic DMARD or a targeted synthetic DMARD was recommended if poor prognostic factors were present, and the treatment target was not achieved with the first conventional synthetic DMARD strategy. The targeted synthetic DMARDs include tofacitinib and baricitinib, synthetic DMARDs specifically designed to target Janus kinases.

EULAR recommended that biologic DMARDs and targeted synthetic DMARDs be combined with a conventional synthetic DMARD as all biologic and targeted synthetic DMARDs are more efficacious in combination therapy compared with monotherapy.

According to EULAR, if a biologic DMARD or targeted synthetic DMARD therapy fails, treatment with another biologic DMARD or targeted synthetic DMARD should be considered. Similarly, if treatment with tumor necrosis factor inhibitor (TNFi) fails, patients may be effectively treated with a different mode of action or a second TNFi therapy.

The National Institute for Health and Care Excellence has recommended Rinvoq, added to standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis in January 2020.

In the UK, Sarilumab with methotrexate, was recommended by NICE in 2017 as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:

• The disease is severe (a disease activity score [DAS28] of more than 5.1) and
• The company provides sarilumab with the discount agreed in the patient access scheme.
• In 2018, an added benefit for Tofacitinib in combination with methotrexate after pretreatment with a conventional synthetic DMARD or with a biological DMARD was not proven for the treatment of adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy by IQWIG, Germany.
• In 2019, IQWIG reported hint of minor added benefit after pretreatment with a conventional synthetic DMARD for Tofacitinib in combination with methotrexate in adults who have had an inadequate response or who were intolerant to a prior DMARD therapy.
• In 2017, IQWIG reported hint of an added benefit for Sarilumab in patients for whom treatment with biologic disease-modifying antirheumatic drugs (bDMARD) is indicated for the first time and who do not tolerate MTX. Added benefits were not proven for other patient groups.

KOL Views

To keep up with current market trends, the publisher takes KOLs and SME's opinion working in RA domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or RA market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the RA Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of RA, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the RA epidemiology and treatment in the 7MM.
• Additionally, an RA-inclusive account of both the current and emerging therapies for RA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of RA market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global RA market.

Report Highlights

• In the coming years, RA market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence RA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for RA. Launch of emerging therapies, will significantly impact the RA market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for RA.
• The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

• AbbVie
• Abivax
• Aclaris Therapeutics
• Akros Pharma/Japan Tobacco
• Bristol Myers Squibb
• Genosco/Oscotec
• Gilead and Galapagos N.V.
• GlaxoSmithKline
• Hope Biosciences
• Izana Bioscience/Takeda
• Merck
• Mesoblast
• Pfizer/Philogen
• R Pharm
• Roche/Genentech
• Taisho Pharmaceuticals/Ablynx
• UCB Pharma/PRA HEALTH SCIENCES
• Viela Bio

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nffwib

View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005631/en/